AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02359136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local infiltration anesthesia using Ropivacaine and Epinephrine
Description: 150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
Study NCT02272062 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision-making tool for coronary artery disease treatment
Description: A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
Study NCT02359136 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: local infiltration anesthesia using saline
Description: 150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
Study NCT02359136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multimodal analgesic regimen
Description: All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
Study NCT02359136 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Multimodal analgesic regimen
Description: All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
Study NCT01462045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based exercise
Description: 8-week program of mindfulness-based stretching and breathing exercises
Study NCT03436745 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
Study NCT03436745 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: In men with prostate cancer, males (pre-castration, n=8-10) will receive oral zolpidem in the form of a 5 mg tablet. Blood samples will be collected for pharmacokinetic analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose. This cohort of men will then undergo androgen deprivation therapy with standard doses of goserelin. When castrate testosterone levels reach \<50 ng/dL (post-castration), they will receive another 5 mg single dose of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Normal healthy females (n=5-8) will receive treatment with a single dose of 5 mg tablet of zolpidem followed by 8-hr PK evaluation of zolpidem and its metabolites. Blood samples will be collected for PK analysis at pre-dose and 0.5, 1, 2, 4, and 8-hours post-dose.
Study NCT02488356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Litramine
Study NCT02488356 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Litramine
Study NCT01951911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
Study NCT01951911 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03855761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: Detailed narrative assessment and person-centered participation in meaningful activities
Study NCT03855761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case management; psychological services
Description: Weekly consultation with case managers to address housing and therapy needs
Study NCT01948518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral sildenafil 20 mg
Description: A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
Study NCT00949806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT (intradermal injection)
Description: Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.~Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient.
Study NCT03955120 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dayzz mobile sleep training
Description: 1. The dayzz digital sleep program provides each user with relevant educational materials (depending on their sleep condition), sleep tracking, and sleep or health-related tasks or challenges pertaining to their sleep or sleep difficulties.~2. Each app user is matched with a sleep trainer who will communicate with them via a chat option within the dayzz app and who will support the participants with any sleep training issues or technical aspects of all app for the duration of the treatment program.~3. Participants receive a wrist-worn device for monitoring sleep and activity patterns, a Fitbit fitness tracker (www.fitbit.com), to be worn for the duration of the study.
Study NCT03955120 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Standard medical care for specific sleep condition
Study NCT02283333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BATE-G
Description: Behavioral Activation and Therapeutic Exposure - Grief therapy is delivered in 7 weekly sessions to the participant.
Study NCT02283333 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Cognitive Restructuring and Supportive Grief Counseling is delivered in 7 weekly sessions to the participant.
Study NCT04350372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip Procedure
Description: MitraClip procedure with MitraClip NT System
Study NCT02792036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye).
Study NCT02792036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maxitrol®
Description: Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
Study NCT02792036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Focal Therapy
Description: Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
Study NCT02792036 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plaque Radiotherapy
Description: Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
Study NCT00388375 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Ultrasound
Description: limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
Study NCT00209742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin
Description: P.O. everyday
Study NCT01656018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC278, Long acting (LA)
Description: TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
Study NCT02607033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
Study NCT02607033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
Study NCT02607033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
Study NCT00525330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104 QD Drug: Placebo Drug: Metformin
Description: KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
Study NCT00525330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug: Metformin
Description: Two tablets 15 to 30 minutes before each meal, morning and evening.
Study NCT00525330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRP-104 BID Drug: Placebo Drug: Metformin
Description: KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
Study NCT01679639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Single dose of aleglitazar in Periods 1, 2, 3
Study NCT01679639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampicin
Description: Single dose in Periods 1 and 2; multiple doses in Period 3
Study NCT04331938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regional anesthetic SPG block-bilateral
Description: Patients will receive a 5mL injection comprised of 4.5mL 1% bupivacaine and 0.5mL of dexamethasone (10mg/mL) directed towards the sphenopalatine ganglion on each side (5 mL on each side)
Study NCT02571192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHP626
Description: single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
Study NCT02571192 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5.95 μCi RAD
Study NCT03875859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remetinostat
Description: Topical 1% remetinostat gel
Study NCT02711735 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RUTI® Therapeutic vaccine
Description: Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
Study NCT02711735 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Matching RUTI® Placebo
Description: Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
Study NCT02777814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: anti hepatitis B virus
Study NCT02777814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: anti hepatitis B virus
Study NCT04040023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron and vitamin Deficiencies Correction Program
Description: Preoperative:~For patient with iron deficiency: Intravenous iron supplementation For patient with folic acid or vitamin B12 deficiency : oral vitamin supplementation For patient with anemia: pre operative erythropoietin injections~Postoperative:~Systematic iron supplementation
Study NCT04040023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PBMi: Training program to improve transfusion practices
Description: Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
Study NCT04040023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PBMi: Training program to improve transfusion practices
Description: Training program to sensitize health care staff to streamline the use of transfusion targeting the following points: limit perioperative and post operative hemodilution; to adapt the transfusion threshold to the tolerance of the patient to anemia in per and postoperative; justify the use of RBC transfusion by setting up a questionnaire; encourage transfusion of RBC unit by unit.
Study NCT05387850 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00665938 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics
Study NCT00665938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)~Arm 2. partially hydrolyzed infant formula with probiotics~Arm 3. extensively hydrolyzed infant formula with probiotics
Study NCT00555386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy and Selenium
Description: 6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
Study NCT00555386 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soy and Selenium
Description: 6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
Study NCT03547700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romidepsin
Description: Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.
Study NCT03547700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib is a reversible proteasome inhibitor. Ixazomib preferentially binds and inhibits the chymotrypsin-like activity of the beta 5 subunit of the 20S proteasome.
Study NCT02752906 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular
Study NCT02752906 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: 0.5 mL, Intramuscular
Study NCT01069809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-004
Description: HIV-1 Immune Therapy
Study NCT03484416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium Carbonate 1500 Mg with Vitamin D
Description: Patients in the routine calcium group received oral supplements of 1,500 mg/day elemental calcium and 1,000 IU/day cholecalciferol (Dicamax 1000) for 2 weeks, whereas control group did not
Study NCT03884296 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: FluMist
Description: Quadrivalent, live, attenuated influenza vaccine, intranasal spray
Study NCT04454879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Patients in the standard dosage group will receive starting dosage of roxadustat 100 mg, three times per week for weight 45-60kg and 120 mg, three times per week for weight greater than 60kg. Patients in the lower dosage group will receive the starting dosage of roxadustat 50 mg, three times per week for weight lower than 50kg, 70 mg, three times per week for weight 50-70kg, 90 mg, three times per week for weight 70-90kg and 110 mg, three times per week for weight 90-110kg, respectively.
Study NCT01308567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form: Solution for injection; Route of administration: Intravenous
Study NCT01308567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel (XRP6976)
Description: Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
Study NCT01308567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT01308567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Pharmaceutical form: Tablet; Route of administration: Oral
Study NCT01612312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thrombectomy
Description: Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
Study NCT01612312 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard percutaneous coronary intervention
Description: In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
Study NCT00387452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise and Strength Exercise
Description: 6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
Study NCT00387452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: 6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
Study NCT04029909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan 0.6mg/m2/d
Description: 0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan
Study NCT04029909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.8mg/m2/d
Description: 0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan
Study NCT04029909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4mg/m2/d
Description: 0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan
Study NCT00280228 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adolescent Skills Parent Management Parent-Adol Negotiation
Description: Acute treatment for 12 weeks followed by three monthly booster sessions.
Study NCT00280228 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Standard outpatient treatment for behavioral problems and substance use